The role of PM2.5 in the pathogenesis of allergic rhinitis and its clinical intervention

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046290

Enrollment

Unknown

Registered

2021-05-12

Start date

2022-01-01

Completion date

Unknown

Last updated

2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Interventions

Control group:drug application

Experimental group1:NAC+drug application

Experimental group2: AR patients with long term use of NAC for 1 year, routine therapy

Experimental group:AR patients with routine therapy, without NAC

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Allergic rhinitis patients aged 18 to 70 years.

Exclusion criteria

Exclusion criteria: Patient with severe basic diseases who can not accept our treatment plan.

Design outcomes

Primary

Measure	Time frame
Visual scale score;Serum Immunoglobulin E;Th2 cytokine;Th1 cytokine;	—

Countries

China

Contacts

Public ContactHuang Yu

Huadong Hospital, Fudan University

huangyu1220@hotmail.com+86 13381758993

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026